| Back |
|
| For Winning performance in tough bacterial skin infections |
| Product Name: |
| Ointment |
| Mupirocin 2.0% w/w |
| Tough performer for tough tracks |
| An inhibitor of bacterial protein synthesis |
| Targets primarily Gm +ve organisms, especially S. aureus, S. epidermidis and most streptococci |
| Useful for eradication of S. aureus from the anterior nares |
| Very low MIC's |
|
| Excellent Susceptibility
|
| * Most strains of MRSA, as well as MSSA, are susceptible to Mupirocin
|
| Superior to other Topical / Oral Treatments
|
| * Mupirocin is superior to topical Neomycin / Polymixin B, oral Erythromycin and oral Cephalexin
|
| Staphylococcus aureus and group A streptococci are the most dominant pathogens involved in the primary & secondary infection of the skin & minor skin wounds in outpatient settings.
|
|
| FURUNCULOSIS
|
| FOLLICULITIS
|
| IMPETIGO
|
| SECONDARY INFECTION ECZEMA
|
| BURNS
|
| LACERATIONS
|
| LEG ULCERS
|
|
Medical Jr.
| 1. Proceedings from a Clinical Round Table Cutis 2003; 71: 4-24
|
| 2. Am. J. Clin. Dermatol 2004; 5(4): 239-259
|
| 3. Am. J. Clin. Dermatol 2004
|
| 4. Antimicrobial Agent and Dermatology, 2000; P 255-260
|
|
| |
|
 |